🌎 Qiagen N.V. is a Dutch holding company and global provider of molecular diagnostics and life sciences solutions.
Core activities:
Sample processing technologies: Extraction and processing of DNA, RNA, and proteins from blood, tissue, and other materials.
Analysis technologies: Preparation of biomolecules for analysis.
Bioinformatics: Software and knowledge bases for data interpretation and practical applications.
Key products and platforms:
QuantiFERON: A test for the diagnosis of latent tuberculosis
QIAstat-Dx: A syndromic testing system for the simultaneous detection of a broad range of pathogens
QIAcuity: A digital PCR system
QIAGEN Digital Insights (QDI): A bioinformatics division
The company serves more than 500,000 customers worldwide in the life sciences (academic institutions, pharmaceutical R&D, forensic medicine) and molecular diagnostics.
In the second quarter of 2025, revenue reached $533.54 million, exceeding the consensus estimate.
The company expects to achieve its mid-term adjusted operating margin target of 31% by 2025, above its initial 2028 guidance.
Management increased its full-year 2025 adjusted earnings per share guidance to approximately $2.35 per year from the previous $2.28.
In 2025, Qiagen received CE-IVDR certification for its entire QIAstat-Dx portfolio in Europe and US FDA approval for the QIAstat-Dx Rise system.
The stock is trading broadly sideways at the upper end of the channel.
Core activities:
Sample processing technologies: Extraction and processing of DNA, RNA, and proteins from blood, tissue, and other materials.
Analysis technologies: Preparation of biomolecules for analysis.
Bioinformatics: Software and knowledge bases for data interpretation and practical applications.
Key products and platforms:
QuantiFERON: A test for the diagnosis of latent tuberculosis
QIAstat-Dx: A syndromic testing system for the simultaneous detection of a broad range of pathogens
QIAcuity: A digital PCR system
QIAGEN Digital Insights (QDI): A bioinformatics division
The company serves more than 500,000 customers worldwide in the life sciences (academic institutions, pharmaceutical R&D, forensic medicine) and molecular diagnostics.
In the second quarter of 2025, revenue reached $533.54 million, exceeding the consensus estimate.
The company expects to achieve its mid-term adjusted operating margin target of 31% by 2025, above its initial 2028 guidance.
Management increased its full-year 2025 adjusted earnings per share guidance to approximately $2.35 per year from the previous $2.28.
In 2025, Qiagen received CE-IVDR certification for its entire QIAstat-Dx portfolio in Europe and US FDA approval for the QIAstat-Dx Rise system.
The stock is trading broadly sideways at the upper end of the channel.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.